Final, Group 3, Phase II Trials, page-2

I have accumulated over the past 5 years to build a substantial holding over this period. With a major milestone now so close I certainly won’t be parting with a single share.

I can’t understand how the market cap of this company has remained at $50M as the phase 2 trial progresses in line with plan and the phase 1 patients continue to improve several years after implant. IIL for example who are currently in phase 2 trials with results expected at the same time as NTCELL has increase to a market cap of $300M.

Despite the lack of media attention when phase 2 results are released the results will speak for themselves where long term holders will be rewarded. 2017 is a make or break year for LCT, we'll either be at 2 cents or 50 cents by the end of the year….